An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
Early and locally advanced breast cancer: diagnosis and management.
London: National Institute for Health and Care Excellence (NICE); 2024 Jan 16. (NICE Guideline, No. 101.)
Addendum to Clinical Guideline 81, Advanced Breast Cancer.
London: National Institute for Health and Care Excellence (NICE); 2017 Aug. (Clinical Guideline Addendum, No. 81.2.)
NICE Evidence Reviews Collection [Internet].
London: National Institute for Health and Care Excellence (NICE); 2016-.
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach [Internet].
Geneva: World Health Organization; 2021 Jul.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
Ravulizumab (Ultomiris): CADTH Reimbursement Reviews and Recommendations: Therapeutic area: Paroxysmal nocturnal hemoglobinuria [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Apr.
Sotorasib (Lumakras): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Kirsten rat sarcoma viral oncogene homologue (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) who have received at least one prior systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Atezolizumab (Tecentriq): CADTH Reimbursement Recommendation: Indication: As monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non–small cell lung cancer whose tumours have programmed death-ligand 1 expression on 50% or more of tumour cells [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Dostarlimab (Jemperli): CADTH Reimbursement Recommendation: Indication: Dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on